How to Buy Bliss GVS Pharma Ltd Shares?
You can easily buy the stocks/shares of Bliss GVS Pharma Ltd (BLISSGVS) on Tickertape or through broker platform by opening a Demat & Trading account onlineWhat is the Share Price of Bliss GVS Pharma Ltd?
The stock prices are volatile and keep changing through the day depending upon various factors and market conditions. The Share price of BLISSGVS as on 15th May 2025 is ₹117.17What is the return on Bliss GVS Pharma Ltd share?
The past returns of Bliss GVS Pharma Ltd (BLISSGVS) share are- Past 1 week: N/A
- Past 1 month: -96.88
- Past 3 months: 30.63
- Past 6 months: -15.29
- Past 1 year: 41.69
- Past 3 years: 88.75
- Past 5 years: 40.65
What is the Dividend yield % on Bliss GVS Pharma Ltd share?
The current dividend yield of Bliss GVS Pharma Ltd (BLISSGVS) is 0.33What is the Market Cap of Bliss GVS Pharma Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Bliss GVS Pharma Ltd (BLISSGVS) is ₹1572.22Cr as of 15th May 2025What is the 52 Week High and Low of Bliss GVS Pharma Ltd?
The 52-week high and low of Bliss GVS Pharma Ltd (BLISSGVS) is ₹185.50 and ₹101.01.What is the PE and PB ratio of Bliss GVS Pharma Ltd?
The P/E (price-to-earnings) and P/B (price-to-book) ratios of Bliss GVS Pharma Ltd are 18.65 and 1.57 respectively.Which sector does Bliss GVS Pharma Ltd belong to?
Bliss GVS Pharma Ltd (BLISSGVS) belongs to the Health Care sector & Pharmaceuticals sub-sector.What are the peers or stocks similar to Bliss GVS Pharma Ltd?
The peers or stocks similar to Bliss GVS Pharma Ltd are: and many others.Can't decide whether or not to buy Bliss GVS Pharma Ltd?
Worry no more! Login to Tickertape and check out Bliss GVS Pharma Ltd (BLISSGVS) scorecard & all the relevant insights today5. Test Stocks FAQ What is the 52 Week High and Low of Bliss GVS Pharma Ltd?
The 52-week high and low of Bliss GVS Pharma Ltd (BLISSGVS) is ₹185.50 and ₹101.01.1. Test Stocks FAQ for Bliss GVS Pharma Ltd Shares?
You can easily buy the stocks/shares of Bliss GVS Pharma Ltd (BLISSGVS) on Tickertape or through broker platform by opening a Google & Trading account online3. Test Stocks FAQ What is the Share Price of Bliss GVS Pharma Ltd?
The stock prices are volatile and keep changing through the day depending upon various factors and market conditions. The Share price of BLISSGVS as on 15th May 2025 is ₹117.17
Bliss GVS Pharma Ltd
BLISSGVS Share Price
117.171.48% (-1.76)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
BLISSGVS Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
BLISSGVS Performance & Key Metrics
BLISSGVS Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 18.65 | 1.57 | 0.33% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.21 | 6.66 | 0.83% |
BLISSGVS Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
BLISSGVS Company Profile
Bliss GVS Pharma Limited is engaged in developing, manufacturing and marketing pharmaceutical formulations.
SUNPHARMA
PE Ratio
37.00
37.00
1Y Return
11.72%
11.72%
Buy Reco %
89.19
89.19
CIPLA
PE Ratio
23.03
23.03
1Y Return
2.55%
2.55%
Buy Reco %
71.05
71.05
DRREDDY
PE Ratio
20.02
20.02
1Y Return
11.76%
11.76%
Buy Reco %
82.05
82.05
TORNTPHARM
PE Ratio
57.53
57.53
1Y Return
13.13%
13.13%
Buy Reco %
67.74
67.74
MANKIND
PE Ratio
49.29
49.29
1Y Return
6.30%
6.30%
Buy Reco %
—
—
BLISSGVS Sentiment Analysis
BLISSGVS Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
BLISSGVS Stock Summary · January 2025
Company is navigating a complex landscape characterized by declining market share in deposits, challenges in meeting Priority Sector Lending (PSL) obligations, and fluctuations in current account flows. Despite these hurdles, the bank is focusing on enhancing customer engagement and service delivery to drive deposit growth, with recent monthly inflows showing a positive trend. The management emphasizes a strategic approach to maintaining profitability over aggressive expansion, particularly in light of competitive pressures and a tight liquidity environment. Efforts to improve operational efficiencies through digitization and a commitment to stable cost management are underway, alongside a proactive strategy to reduce borrowings and strengthen the balance sheet. Overall, while facing short-term challenges, the bank remains optimistic about future performance and is committed to achieving sustainable growth through strategic investments and improved customer outreach.
BLISSGVS Stock Growth Drivers
BLISSGVS Stock Growth Drivers
5Focus on Sustainable Growth
Company is prioritizing profitable growth over mere expansion, emphasizing a strategy that encourages ground-level teams
Stable Financial Metrics
The company has maintained a return on assets (ROA) of 1.9% post-merger, showcasing stability in
BLISSGVS Stock Challenges
BLISSGVS Stock Challenges
5Deposit Growth Shortfalls
The company has experienced deposit growth that has not met expectations, attributed to seasonal trends
Loan Growth Concerns
There is uncertainty regarding the company's loan deposit ratio (LDR) and its implications for loan
BLISSGVS Forecast
What are forecasts?
What are forecasts?
Forecasting uses historical data as inputs to make informed predictive estimates determining the direction of future trends. Price, revenue & earnings forecasts represent where the stock level, business prospects and profits are potentially expected to be at the end of the forecast period
BLISSGVS Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
BLISSGVS
BLISSGVS
Income
Balance Sheet
Cash Flow
Annual Normal View
BLISSGVS Income Statement
BLISSGVS Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 810.94 | 841.18 | 936.20 | 728.50 | 597.43 | 778.94 | 769.38 | 798.98 | 846.22 | 846.22 | ||||||||||
Raw Materials | 368.69 | 391.70 | 618.79 | 435.67 | 341.59 | 420.18 | 374.38 | 390.46 | 683.04 | 683.04 | ||||||||||
| Power & Fuel Cost | 5.58 | 5.49 | 4.76 | 5.88 | 8.14 | 8.25 | 7.13 | 10.43 | ||||||||||||
| Employee Cost | 61.35 | 69.23 | 42.32 | 53.69 | 68.09 | 76.15 | 86.17 | 95.58 | ||||||||||||
| Selling & Administrative Expenses | 117.90 | 87.57 | 49.96 | 45.30 | 44.91 | 80.65 | 80.45 | 85.89 | ||||||||||||
| Operating & Other expenses | 42.19 | 97.72 | 25.10 | 38.83 | 7.82 | 117.48 | 86.13 | 66.45 | ||||||||||||
EBITDA | 215.23 | 189.47 | 195.27 | 149.13 | 126.88 | 76.23 | 135.12 | 150.17 | 163.18 | 163.18 | ||||||||||
| Depreciation/Amortization | 20.14 | 21.38 | 8.94 | 12.59 | 17.23 | 17.33 | 18.67 | 26.38 | 29.42 | 29.42 | ||||||||||
| PBIT | 195.09 | 168.09 | 186.33 | 136.54 | 109.65 | 58.90 | 116.45 | 123.79 | 133.76 | 133.76 | ||||||||||
| Interest & Other Items | 19.69 | 22.80 | 4.41 | 7.57 | 5.51 | 4.74 | 10.36 | 6.91 | 8.12 | 8.12 | ||||||||||
| PBT | 175.40 | 145.29 | 181.92 | 128.97 | 104.14 | 54.16 | 106.09 | 116.88 | 125.64 | 125.64 | ||||||||||
| Taxes & Other Items | 93.36 | 86.51 | 58.19 | 31.71 | 35.63 | 39.13 | 35.22 | 41.41 | 41.35 | 41.33 | ||||||||||
| Net Income | 82.04 | 58.78 | 123.73 | 97.26 | 68.51 | 15.03 | 70.87 | 75.47 | 84.29 | 84.31 | ||||||||||
| EPS | 7.95 | 5.70 | 12.00 | 9.43 | 6.64 | 1.45 | 6.82 | 7.23 | 8.02 | 8.05 | ||||||||||
| DPS | 0.60 | 1.00 | 1.00 | 0.50 | 0.50 | 0.50 | 0.50 | 0.50 | 0.50 | 1.00 | ||||||||||
| Payout ratio | 0.08 | 0.18 | 0.08 | 0.05 | 0.08 | 0.34 | 0.07 | 0.07 | 0.06 | 0.12 |
BLISSGVS Company Updates
FY 2019FY 2019
Investor Presentation
May 21PDF
Feb 1PDF
Nov 3PDF
Aug 9PDF
BLISSGVS Stock Peers
What are peers and why compare against them?
What are peers and why compare against them?
A stock's peers are companies which have similar business interests, operations and belong to the same industry sector. Comparing various metrics against peers can give valuable insights on whether the company's stock is over/under-valued and the company's growth outlook vs the industry as a whole
BLISSGVS Past Performance & Peer Comparison
BLISSGVS Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation-basic on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation-basic on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Bliss GVS Pharma Ltd | 18.65 | 1.57 | 0.33% |
| Sun Pharmaceutical Industries Ltd | 37.00 | 6.03 | 0.95% |
| Cipla Ltd | 23.03 | 4.53 | 1.06% |
| Dr Reddy's Laboratories Ltd | 20.02 | 4.01 | 0.59% |
BLISSGVS Stock Price Comparison
Compare BLISSGVS with any stock or ETFCompare BLISSGVS with any stock or ETF
BLISSGVS
BLISSGVS Holdings
BLISSGVS Shareholdings
What are shareholdings?
What are shareholdings?
Apart from retail investors, a company’s shares are held by promoters, foreign & domestic institutions (large investors) and mutual funds. Promoters are the ship captains and control the company’s direction. Along with institutional and mutual fund holdings, a change in their holdings can indicate performance outlook for the stock
BLISSGVS Promoter Holdings Trend
BLISSGVS Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
BLISSGVS Institutional Holdings Trend
BLISSGVS Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
BLISSGVS Shareholding Pattern
BLISSGVS Shareholding Pattern
BLISSGVS Shareholding History
BLISSGVS Shareholding History
Foreign Institutions
Mutual Funds Invested in BLISSGVS
Mutual Funds Invested in BLISSGVS
No mutual funds holding trends are available
Top 1 Mutual Funds holding Bliss GVS Pharma Ltd
| Funds (Top 1) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0008% | Percentage of the fund’s portfolio invested in the stock 0.07% | Change in the portfolio weight of the stock over the last 3 months 0.07% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 79/102 (+22) |
Compare 3-month MF holding change on Screener
smallcases containing BLISSGVS stock
smallcases containing BLISSGVS stock
Looks like this stock is not in any smallcase yet.
BLISSGVS Events
BLISSGVS Events
BLISSGVS Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
BLISSGVS has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.33%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹3.33 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
What are dividends?
What are dividends?
Dividends are a portion of earnings that a company distributes to all its shareholders every year. Dividend return is one of the most important things to be considered while investing for long term. It’s the additional return on top of what investors earn through price appreciation
BLISSGVS Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
BLISSGVS has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.33%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹3.33 every year
BLISSGVS Upcoming Dividends
BLISSGVS Upcoming Dividends
No upcoming dividends are available
BLISSGVS Past Dividends
BLISSGVS Past Dividends
Cash Dividend
Ex DateEx DateJul 18, 2024
Final
Final | Div/Share: ₹0.50
Dividend/Share
₹0.50
Ex DateEx Date
Jul 18, 2024
Cash Dividend
Ex DateEx DateJul 17, 2024
Final
Final | Div/Share: ₹0.50
Dividend/Share
₹0.50
Ex DateEx Date
Jul 17, 2024
Cash Dividend
Ex DateEx DateJun 20, 2022
Final
Final | Div/Share: ₹0.50
Dividend/Share
₹0.50
Ex DateEx Date
Jun 20, 2022
Cash Dividend
Ex DateEx DateSep 13, 2021
Final
Final | Div/Share: ₹0.50
Dividend/Share
₹0.50
Ex DateEx Date
Sep 13, 2021
Cash Dividend
Ex DateEx DateSep 17, 2020
Final
Final | Div/Share: ₹0.50
Dividend/Share
₹0.50
Ex DateEx Date
Sep 17, 2020
BLISSGVS Stock News & Opinions
BLISSGVS Stock News & Opinions
Articles & Videos
Corporate
Bliss GVS Pharma allots 75,250 equity shares under ESOP
Bliss GVS Pharma has allotted 75,250 equity shares under ESOP on 06 June 2025. Consequently, the paid up equity share capital has increased to 10,54,45,522 equity shares of Re. 1/- each aggregating Rs. 10,54,45,522 /. Powered by Capital Market - Live
1 week agoCapital Market - Live
Corporate
Bliss GVS Pharma schedules AGM
Bliss GVS Pharma announced that the 40th Annual General Meeting(AGM) of the company will be held on 31 July 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Board of Bliss GVS Pharma recommends final dividend
Bliss GVS Pharma announced that the Board of Directors of the Company at its meeting held on 12 May 2025, inter alia, have recommended the final dividend of Rs 0.5 per equity Share (i.e. 50%) , subject to the approval of the shareholders.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Bliss GVS Pharma reports consolidated net profit of Rs 15.54 crore in the March 2025 quarter
Net profit of Bliss GVS Pharma reported to Rs 15.54 crore in the quarter ended March 2025 as against net loss of Rs 9.15 crore during the previous quarter ended March 2024. Sales declined 0.07% to Rs 197.99 crore in the quarter ended March 2025 as against Rs 198.13 crore during the previous quarter ended March 2024. For the full year,net profit rose 11.73% to Rs 84.30 crore in the year ended March 2025 as against Rs 75.45 crore during the previous year ended March 2024. Sales rose 5.13% to Rs 809.73 crore in the year ended March 2025 as against Rs 770.24 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales197.99198.13 0 809.73770.24 5 OPM %10.6514.31 -15.6519.55 - PBDT31.4832.10 -2 155.06172.45 -10 PBT23.4425.25 -7 125.64146.07 -14 NP15.54-9.15 LP 84.3075.45 12 Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Bliss GVS Pharma reports standalone net profit of Rs 11.45 crore in the March 2025 quarter
Net profit of Bliss GVS Pharma reported to Rs 11.45 crore in the quarter ended March 2025 as against net loss of Rs 11.46 crore during the previous quarter ended March 2024. Sales declined 4.77% to Rs 156.00 crore in the quarter ended March 2025 as against Rs 163.82 crore during the previous quarter ended March 2024. For the full year,net profit rose 36.20% to Rs 68.97 crore in the year ended March 2025 as against Rs 50.64 crore during the previous year ended March 2024. Sales rose 10.20% to Rs 667.20 crore in the year ended March 2025 as against Rs 605.46 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales156.00163.82 -5 667.20605.46 10 OPM %8.8015.36 -13.7317.70 - PBDT21.7932.09 -32 121.22134.86 -10 PBT14.3625.86 -44 94.17111.34 -15 NP11.45-11.46 LP 68.9750.64 36 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Bliss GVS Pharma to announce Quarterly Result
Bliss GVS Pharma will hold a meeting of the Board of Directors of the Company on 12 May 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Bliss GVS Pharma invokes arbitration proceedings against Pan Pharmaceuticals, Kenya
Bliss GVS Pharma had invoked arbitration proceedings against Pan Pharmaceuticals (Nairobi, Kenya) for recovery of its outstanding dues by way of filing a petition seeking appointment of an arbitrator before the Supreme Court of India. The expected recovery arising from the aforementioned arbitration proceedings is estimated at USD 1.69 million. Furthermore, the Company has proactively made appropriate provisions in its books of accounts for the amount recoverable from Pan Pharmaceuticals, thereby ensuring minimal or no adverse financial impact. The quantum of claim will depend upon the outcome of the arbitrating authority.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Bliss GVS Pharma consolidated net profit declines 13.80% in the December 2024 quarter
Net profit of Bliss GVS Pharma declined 13.80% to Rs 23.80 crore in the quarter ended December 2024 as against Rs 27.61 crore during the previous quarter ended December 2023. Sales rose 4.83% to Rs 210.42 crore in the quarter ended December 2024 as against Rs 200.72 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales210.42200.72 5 OPM %14.1521.77 - PBDT43.9747.00 -6 PBT36.4240.04 -9 NP23.8027.61 -14 Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Bliss GVS Pharma schedules board meeting
Bliss GVS Pharma will hold a meeting of the Board of Directors of the Company on 28 January 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Spotlight
Bliss GVS Pharma soars after manufacturing units get GMP certificate from Romania medical authority
In a regulatory filing made on Saturday, the company informed that its manufacturing facilities located at Aliyali Village and Vevoor Village in Palghar district of Maharashtra has received a Certificate of GMP (good manufacturing practice) Compliance from the National Agency for Medicines and Medical Devices of Romania (NAMMDR). The compliance certificate has been granted following an EU GMP inspection that took place on 30th November and 1st December 2023 at the said facilities. Bliss develops and manufactures pharmaceutical formulations mainly for sale in Africa. The company sells formulations in the form of suppositories, pessaries, capsules, tablets, and syrups. It manufactures more than 250 branded formulations in the anti-malarial, anti-fungal, anti-bacterial, anti-biotic, anti-inflammatory, contraceptive, and anti-diabetic segments. Bliss also contract-manufactures suppositories and pessaries for Sun Pharma and Mankind. The company's consolidated net profit declined 42.66% to Rs 24.26 crore despite a 2.74% rise in net sales to Rs 217.68 crore in Q2 FY25 as compared with Q2 FY24. Powered by Capital Market - Live
6 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of -3.12%, vs industry avg of 9.02%
Over the last 5 years, market share decreased from 0.23% to 0.21%
Over the last 5 years, net income has grown at a yearly rate of -9.41%, vs industry avg of 15.29%